S Müller-Rebstein1,2, C Trenkwalder3, W H Oertel4,5, C Culmsee2, G Eckermann6, G U Höglinger7. 1. Klinik für Neurologie, Klinikum rechts der Isar, Technische Universität München und Lehrstuhl für Translationale Neurodegeneration, Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE) München, Feodor-Lynen Str. 17, 81377, München, Deutschland. 2. Institut für Pharmakologie und Klinische Pharmazie, Philipps-Universität Marburg, Marburg, Deutschland. 3. Paracelsus Elena-Klinik Kassel, Klinik für Neurochirurgie, Universitätsmedizin Göttingen, Göttingen, Deutschland. 4. Klinik für Neurologie, Philipps-Universität Marburg, Marburg, Deutschland. 5. Institut für Neurogenomik, Helmholtz Zentrum für Gesundheit und Umwelt München, München, Deutschland. 6. Fachkrankenhaus für Psychiatrie, Psychotherapie, Psychosomatik und Neurologie, Bezirkskrankenhaus Kaufbeuren, Kaufbeuren, Deutschland. 7. Klinik für Neurologie, Klinikum rechts der Isar, Technische Universität München und Lehrstuhl für Translationale Neurodegeneration, Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE) München, Feodor-Lynen Str. 17, 81377, München, Deutschland. Guenter.Hoeglinger@tum.de.
Abstract
BACKGROUND: This overview focuses on the aspects of the pharmacotherapy of Parkinson's disease, which is one of the most common disorders of the nervous system. This article presents the complexity of the pharmacotherapy of geriatric patients with neurological diseases. OBJECTIVES: Information about the potential risk factors and aspects of drug safety in the pharmacotherapy of Parkinson's disease. MATERIALS AND METHODS: Selective literature search using PubMed and the scientific-clinical experience of the authors. RESULTS: Patients with Parkinson's disease are usually geriatric patients with concomitant diseases. As a result they are often treated with comedication which leads to a complex medication regime with more than five drugs. Such polypharmacy increases the risk of adverse drug events due to the rising number of possible interactions and contraindications. To control this risk and maintain a safe therapy, certain measures should be considered. This implies additional need for educational work in order to create awareness regarding potential adverse drug events. In certain cases of diagnosed comorbidities or relevant drug prescriptions in the medication regime, follow-up examinations should be conducted. CONCLUSION: Specific parameters of Parkinson's disease, the health-related quality of life of affected patients and the quality of pharmacotherapeutic drug safety can be improved by targeted monitoring of the medication regime. As a result, the overall drug safety can be increased.
BACKGROUND: This overview focuses on the aspects of the pharmacotherapy of Parkinson's disease, which is one of the most common disorders of the nervous system. This article presents the complexity of the pharmacotherapy of geriatric patients with neurological diseases. OBJECTIVES: Information about the potential risk factors and aspects of drug safety in the pharmacotherapy of Parkinson's disease. MATERIALS AND METHODS: Selective literature search using PubMed and the scientific-clinical experience of the authors. RESULTS:Patients with Parkinson's disease are usually geriatric patients with concomitant diseases. As a result they are often treated with comedication which leads to a complex medication regime with more than five drugs. Such polypharmacy increases the risk of adverse drug events due to the rising number of possible interactions and contraindications. To control this risk and maintain a safe therapy, certain measures should be considered. This implies additional need for educational work in order to create awareness regarding potential adverse drug events. In certain cases of diagnosed comorbidities or relevant drug prescriptions in the medication regime, follow-up examinations should be conducted. CONCLUSION: Specific parameters of Parkinson's disease, the health-related quality of life of affected patients and the quality of pharmacotherapeutic drug safety can be improved by targeted monitoring of the medication regime. As a result, the overall drug safety can be increased.
Entities:
Keywords:
Adverse drug event; Medication management; Neurogeriatrics; Patient compliance; Polypharmacy
Authors: Richard Gray; Natalie Ives; Caroline Rick; Smitaa Patel; Alastair Gray; Crispin Jenkinson; Emma McIntosh; Keith Wheatley; Adrian Williams; Carl E Clarke Journal: Lancet Date: 2014-06-11 Impact factor: 79.321